Analytical Procedures in the Dossier: What ICH Q2(R2) and Q14 Change

The revised ICH Q2(R2) and the new ICH Q14 move analytical procedures from a one-off validation exercise to a lifecycle that starts at development and continues through routine use.

Two guidelines, one lifecycle

ICH Q2(R2) revises the guideline on validation of analytical procedures and now covers a broader range of techniques, including multivariate and spectroscopic methods. ICH Q14 describes how analytical procedures are developed, including the analytical target profile, which defines what the procedure must achieve.

Both guidelines were finalised by ICH in 2023 and are published by the EMA as scientific guidelines. Applicants should check the EMA website for the current status and effective date rather than relying on older summaries.

What this means for Module 3

Analytical procedures appear in 3.2.S.4.2 and 3.2.P.5.2 and their validation in 3.2.S.4.3 and 3.2.P.5.3. Under the enhanced approach described in Q14, the dossier can include additional information on development, robustness and the method operable design region, which can support a more flexible approach to later changes.

  • Define the analytical target profile before choosing the technique.
  • Describe development studies that justify the chosen conditions.
  • Validate against the performance characteristics relevant to the intended use, such as specificity, accuracy, precision and range.
  • Document the link between method performance and the specification limits.

Practical consequences

Even with the minimum approach, reviewers expect validation that matches the purpose of the method. A stability-indicating claim should be supported by forced degradation data. A method for a low-level impurity should show suitable sensitivity near the reporting threshold.

Method transfers between laboratories, particularly to a contract laboratory, need to be reflected in the dossier and in the quality agreement. A procedure validated in one place and run in another without demonstrated equivalence is a frequent inspection finding.

Managing change

A well-documented development package can make later method changes easier to justify, but it does not remove the need to assess the regulatory category of each change under the variations framework. Plan this at the time of writing the dossier, not when a method has to be replaced.

Questions to ask before filing

Is the analytical target profile written down, and does the validation address the performance characteristics that matter for the intended use? Where a method is run by a contract laboratory, has equivalence to the originating laboratory been demonstrated and documented? Are system suitability criteria defined? A short gap review against these questions is usually enough to identify weaknesses before submission.

How PQRA helps

PQRA checks that analytical sections of Module 3 are consistent with the specification and stability data, helps decide how much development information to include, and assesses the variation category when methods change.

Talk to us about your dossier: Contact PQRA

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *